WO2008099829A1 - 実験動物の腸管癒着を形成する方法、腸管癒着実験動物の製造方法、腸管癒着抑制剤のスクリーニング方法及び腸管癒着抑制剤 - Google Patents

実験動物の腸管癒着を形成する方法、腸管癒着実験動物の製造方法、腸管癒着抑制剤のスクリーニング方法及び腸管癒着抑制剤 Download PDF

Info

Publication number
WO2008099829A1
WO2008099829A1 PCT/JP2008/052299 JP2008052299W WO2008099829A1 WO 2008099829 A1 WO2008099829 A1 WO 2008099829A1 JP 2008052299 W JP2008052299 W JP 2008052299W WO 2008099829 A1 WO2008099829 A1 WO 2008099829A1
Authority
WO
WIPO (PCT)
Prior art keywords
intestinal adhesion
experimental animal
preventing agent
intestinal
adhesion
Prior art date
Application number
PCT/JP2008/052299
Other languages
English (en)
French (fr)
Inventor
Tomohiro Yoshimoto
Kenji Nakanishi
Jirou Fujimoto
Original Assignee
Japan Science And Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science And Technology Agency filed Critical Japan Science And Technology Agency
Priority to JP2008558089A priority Critical patent/JP5530635B2/ja
Publication of WO2008099829A1 publication Critical patent/WO2008099829A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma

Abstract

　本発明の実験動物の腸管癒着を形成する方法は、実験動物の腸管を焼灼する焼灼工程を含み、上記焼灼工程では、上記実験動物が有する腸管に、ＩＦＮ－γの発現を誘導する熱量の熱を与える。これにより、所望の程度の腸管癒着を再現性良く形成可能な、実験動物の腸管癒着を形成する方法を提供することができる。また、本発明に係る腸管癒着抑制剤は、ＨＧＦ等のＩＦＮ－γ阻害物質を含み、腸管が侵襲される手術の１日前から当該手術の３０分後までの間に投与される。これにより、腸管癒着を抑制可能な腸管癒着抑制剤を提供することができる。
PCT/JP2008/052299 2007-02-14 2008-02-13 実験動物の腸管癒着を形成する方法、腸管癒着実験動物の製造方法、腸管癒着抑制剤のスクリーニング方法及び腸管癒着抑制剤 WO2008099829A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008558089A JP5530635B2 (ja) 2007-02-14 2008-02-13 腸管癒着抑制剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007033904 2007-02-14
JP2007-033904 2007-02-14

Publications (1)

Publication Number Publication Date
WO2008099829A1 true WO2008099829A1 (ja) 2008-08-21

Family

ID=39690057

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/052299 WO2008099829A1 (ja) 2007-02-14 2008-02-13 実験動物の腸管癒着を形成する方法、腸管癒着実験動物の製造方法、腸管癒着抑制剤のスクリーニング方法及び腸管癒着抑制剤

Country Status (2)

Country Link
JP (1) JP5530635B2 (ja)
WO (1) WO2008099829A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016175931A (ja) * 2011-05-17 2016-10-06 ジョイント ストック カンパニー ”ファーマシンテズ” 癒着の治療及び予防の方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
JP7235249B2 (ja) * 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11511160A (ja) * 1995-08-18 1999-09-28 ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター インターフェロン−ガンマインヒビター含有医薬組成物
JP2003517007A (ja) * 1999-12-15 2003-05-20 エントレメッド インコーポレイテッド 内皮細胞増殖阻害組成物および方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11511160A (ja) * 1995-08-18 1999-09-28 ザ・ビクトリア・ユニバーシティ・オブ・マンチェスター インターフェロン−ガンマインヒビター含有医薬組成物
JP2003517007A (ja) * 1999-12-15 2003-05-20 エントレメッド インコーポレイテッド 内皮細胞増殖阻害組成物および方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BREED K.L. ET AL.: "A neurokinin 1 receptor antagonist decreases postoperative peritoneal adhesion formation and increases peritoneal fibrinolytic activity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 24, 15 June 2004 (2004-06-15), pages 9115 - 9120 *
KOSAKA H. ET AL.: "Atarashii Mouse Fukukonai Yachuku Model no Kakuritsu to Yuchaku Keisei ni Kakawaru Men'ekigakuteki Yoin no Kaiseki", JOURNAL OF JAPAN SURGICAL SOCIETY, no. 108, 10 March 2007 (2007-03-10), pages 708 *
KOSAKA H. ET AL.: "NKT cell-driven IFN-gamma plays on important role in postoperative adhesion formation", PROCEEDINGS OF THE JAPANESE SOCIETY FOR IMMUNOLOGY, vol. 37, 25 October 2007 (2007-10-25), pages 157 *
KUROIWA T. ET AL.: "Hepatocyte growth factor ameliorates acute graft-versus-host disease and promotes hematopoietic function", JOURNAL OF CLINICAL INVESTIGATION, vol. 107, no. 11, 1 June 2001 (2001-06-01), pages 1365 - 1373 *
PITTAWAY D.E. ET AL.: "A comparison of the CO2 laser and electrocautery on postoperative intraperitoneal adhesion formation in rabbits", FERTILIGY AND STERILITY, vol. 40, no. 3, September 1983 (1983-09-01), pages 366 - 368 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016175931A (ja) * 2011-05-17 2016-10-06 ジョイント ストック カンパニー ”ファーマシンテズ” 癒着の治療及び予防の方法

Also Published As

Publication number Publication date
JPWO2008099829A1 (ja) 2010-05-27
JP5530635B2 (ja) 2014-06-25

Similar Documents

Publication Publication Date Title
WO2007087560A3 (en) Stroke inducing and monitoring system and method for using the same
EP1719793A4 (en) POLYMER AND MANUFACTURING METHOD THEREFOR, COMPOSITION FOR FORMING AN INSULATING FILM AND PRODUCTION METHOD THEREFOR
WO2006014353A3 (en) Glycogen or polysaccharide storage disease treatment method
WO2008102363A3 (en) Treating weakened vessel wall such as vulnerable plaque or aneurysms
EP1773405A4 (en) METHOD FOR DIAGNOSIS, MONITORING AND TREATMENT OF LUNG DISEASES
IL195178A0 (en) 4,5-diphenyl-pyrimidinyl-oxy or-mercapto substituted carboxylic acids, method for the production and use thereof as medicaments
EP2201847A4 (en) FROZEN NOODLES, PROCESS FOR PREPARING FROZEN NOODLES AND COATING SOLUTION TO PREVENT FREEZING FIRES
MX2007006311A (es) Acidos hidroxibifenilcarboxilicos y derivados, metodo para producirlos y su uso.
WO2005117811A3 (en) Physiological cooling compositions
AU2003248245A1 (en) Remedies for diseases caused by vascular contraction or dilation
TNSN08443A1 (en) Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors
WO2007118185A3 (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
IL195179A0 (en) Phenylamino-benzoxazole substituted carboxylic acids, method for their production and use thereof as medicaments
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
WO2008112437A3 (en) Repair of defect in inguinal canal and other muscular structures
WO2008099829A1 (ja) 実験動物の腸管癒着を形成する方法、腸管癒着実験動物の製造方法、腸管癒着抑制剤のスクリーニング方法及び腸管癒着抑制剤
WO2006012517A3 (en) Food sweetener
WO2004075857A3 (en) Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
WO2004017948A8 (en) Use of lck inhibitor for treatment of immunologic diseases
WO2009000392A3 (de) Verfahren zum fügen von hybridbauteilen
WO2008145842A3 (fr) Dérivés de triazolopyridine-carboxamides, leur préparation et leur application en thérapeutique
HK1102099A1 (en) Method of producing frozen dough, and related products
WO2008019200A3 (en) Cold seal release films and methods of making same
WO2004043348A3 (en) Histone deacetylase inhibitors for treating degenerative diseases of the eye
PL366690A1 (en) New derivatives of 4,5,6,7-tetrabromobenzimidazole and method for their obtaining

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711157

Country of ref document: EP

Kind code of ref document: A1

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2008558089

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08711157

Country of ref document: EP

Kind code of ref document: A1